GPR35

Second Prestigious BMC Grant in Under a Year will Enable Creation and Validation of Biomarker-Driven Process for Precisely Selecting Patients Most Likely to Respond to GPR35 Inhibition Company Narrows Initial Therapeutic Focus to Ulcerative Colitis with Precision Medicine Strategy for Clinical Development Validating Non-Dilutive Grant Funding Supports Ongoing Fundraising Efforts as Company Continues on Path Toward Clinic OXFORD, United Kingdom, July 2, 2024 /PRNewswire/ -- ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today announced that the company, along with its long-standing academic collaborator, Nicole Kaneider, Ph.D., of the University of Cambridge, have been awarded a highly competitive Biomedical Catalyst (BMC) grant from Innovate UK, the UK's innovation agency. The grant, for a total of £643,371 (~$817,000), will fund preclinical research designed to enable the company to pursue a precision medicine approach to patient selection for the clinical development of its first-in-class GPR35 inhibitors. While the company's unique approach to GPR35 inhibition has potential application broadly across GI disease and cancers, ThirtyFiveBio is focusing its initial development activities on inflammatory GI conditions driven by epithelial dysfunction such as ulcerative colitis. For this research project, ThirtyFiveBio and Dr. Kaneider will work collaboratively to identify subsets of patients who are enriched for GPR35 inhibitor responsiveness based on their unique genetic signatures. This will involve the deployment of bioinformatics and multi-omics to analyze clinical datasets and cross-reference those with preclinical data generated with relevant cell line and unique disease model platforms. Once this blueprint for GPR35 inhibitor responsiveness is created, the researchers will work to validate the genetic signature in additional preclinical studies, thus providing the company with biomarkers that can be used for precision patient selection in planned clinical trials. "Receiving a second BMC grant from Innovate UK in less than a year is incredibly validating for the ThirtyFiveBio team and the pioneering work we are undertaking on GPR35 inhibition. As we continue to advance our preclinical program in this area, we learn more about the key role that GPR35 plays within the upstream causal biology of inflammatory GI diseases. It is this opportunity to engage at the source of disease activity that has driven our decision to elevate conditions such as ulcerative colitis to the top of our target indication list," said James Westcott, Ph.D., chief executive officer of ThirtyFiveBio. "We look forward to continuing to collaborate with Dr. Kaneider on this latest project and benefiting from her significant expertise on the biological function of GPR35 in GI disease. This work will be instrumental in supporting both the advancement of our GPR35 inhibitor program toward the clinic, as well as our ongoing fundraising efforts." The role of GPR35 in GI diseases is genetically validated and provides a differentiated approach to disease treatment by focusing on underlying and unresolved epithelial and myeloid cell dysfunction, rather than directly addressing inflammation. Several drug developers are advancing programs designed to address the target, though to date, virtually all these efforts have been focused on increasing the activity of GPR35 with targeted agonists. However, important recent scientific findings, including key insights from the ThirtyFiveBio team, support the hypothesis that GPR35 antagonism may represent a more appropriate therapeutic approach by blocking unwanted GPR35 signaling. Based on this evolved scientific perspective, supported by the company's work with several world-leading, academic GPR35 specialists, ThirtyFiveBio is uniquely pursuing antagonism of the target with first-in-class small molecule GPR35 inhibitors. Supporting the company's focus on GPR35 inhibition is a collection of pre-clinical data generated by its scientists that highlights the association between GPR35 mutations and GI diseases. This includes research showing that GPR35 variants are linked to inflammatory bowel disease, and that GPR35 expression is upregulated in GI cancers. The company and Dr. Kaneider have also shown that pathogenic mutations of GPR35 drive its increased expression and function. Furthermore, study results have demonstrated that commonly dysregulated GI-cancer genes can be reversed by knocking out GPR35 in cancer cells. Taken together, these findings provide compelling evidence that hyperactive genetic mutations within GPR35 contribute to a range of GI disease processes, and that inhibiting GPR35 activity may have therapeutic utility in these diseases. About ThirtyFiveBio ThirtyFiveBio Limited is a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease. The company has built scientific thought leadership in the biology of GPR35 and the role that it plays in GI disease, including digestive tract colitis and cancers. ThirtyFiveBio has leveraged its fully enabled drug discovery platform to identify multiple unique families of first-in-class small-molecule GPR35 inhibitors that it is advancing through lead optimization activities. Created by M:M Bio and Canaan Partners, the company has raised $20 million in seed financing to date. ThirtyFiveBio is headquartered at the Innovation Centre on Milton Park, a key science precinct south of Oxford, UK. For more information, please visit: About Innovate UK Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. We connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth. We fund business and research collaborations to accelerate innovation and drive business investment into R&D. Our support is available to businesses across all economic sectors, value chains and UK regions. Innovate UK is part of UK Research and Innovation. For more information visit Contacts: ThirtyFiveBio James Westcott Chief Executive Officer P: +44 (0)1235 644980 [email protected] Vida Strategic Partners (on behalf of ThirtyFiveBio) Tim Brons (Media) 415-675-7402 [email protected] SOURCE ThirtyFiveBio

Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2024. The full report can be found here. Chris Cargill, President and CEO of Nxera, commented: “We entered 2024 with a clear vision to capitalize on a number of strategic opportunities and build on the strong foundations we have created, positioning the business for the next stage of its journey to become a leading biopharmaceutical company in Japan. The last three months, defined by our bold actions, have been a testament to this. “A key milestone this quarter has been the change of company name from Sosei Heptares to Nxera Pharma and the unveiling of a bold new brand and identity that captures our ambition to be pioneers of the next era of biopharmaceuticals and medicine. The decision to make this change was driven by the significant growth and development of the business, which has been accelerated through several key strategic acquisitions in recent years, and progress made advancing our extensive pipeline both in-house and with our partners. “I extend my gratitude to our brilliant team in Japan, the UK, South Korea and Switzerland whose dedication and expertise has enabled these significant achievements and will empower our future success.” Operational Highlights for Q1 2024 Corporate highlights Change of company name to Nxera Pharma Approved on 27 March at the Company’s 34th Annual Shareholders’ Meeting and came into effect on 1 April 2024 Appointment of Chief Operating Officer, Toshihiro Maeda Mr Maeda, an experienced pharmaceutical executive, is leading the post-acquisition integration of the Nxera Pharma Japan (“NPJ”) and Nxera Pharma Korea (“NPK”) businesses into Nxera and will be responsible for all technical operations Progress with in-house programs First subject dosed in a Phase 1 trial with NXE0033744, a novel, potent, selective and gut-restricted EP4 receptor agonist discovered by Nxera in development for the treatment of Inflammatory Bowel Disease (IBD) Regained full ownership from GSK of NXE0027477, a clinic-ready, highly selective, first-in-class, oral GPR35 agonist in development as a potential new treatment for IBD Nxera expects to determine the optimal strategy for further clinical development of the program, which could include in-house development and/or re-partnering Progress with partnered programs Entered a global collaboration and exclusive option-to-license agreement with Boehringer Ingelheim to develop first-in-class treatments targeting all symptoms of schizophrenia Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Nxera with the potential to simultaneously address positive, negative and cognitive symptoms of schizophrenia Nxera received EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totalling up to EUR 670 million plus tiered royalties US$2.5 million milestone payment received from Formosa Pharmaceuticals for US approval of APP13007 (originally designed and developed at Activus Pharma, formerly a wholly owned subsidiary of the Company), for the treatment of post-operative inflammation and pain following ocular surgery Post-period events Exclusive supply and distribution agreement with Handok for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea PIVLAZ™ is the first drug approved in South Korea for the prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage (aSAH) and is expected to become commercially available in South Korea in early 2025 US$15 million payment from Neurocrine Biosciences triggered by successful development progress of partnered schizophrenia candidate NBI-1117568 NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration Successful completion of long-term preclinical toxicity program supports safe, chronic dosing of NBI-1117568 in future clinical trials Joined the World Orphan Drug Alliance (“WODA”) to represent WODA in Japan and South Korea Through the Alliance and its global networks, Nxera will gain access to a pipeline of novel medicines targeting rare or orphan diseases as potential licensing opportunities (with no obligation) for its late clinical stage and commercialization operations in these regions Senior team strengthened with appointment of experienced senior strategy consultant Patrick Branch as Head of Business Development for Japan and APAC Financial Highlights for the Three-month Period ended 31 March 2024 Revenue totalled JPY 4,611 million (US$31.1 million*), an increase of JPY 3,668 million (US$23.9 million) vs. the prior corresponding period. The increase is primarily due to the inclusion of NPJ in the scope of consolidation from July 2023, which resulted in the addition of PIVLAZ® sales. R&D expenses totalled JPY 3,163 million (US$21.3 million), an increase of JPY 1,206 million (US$6.5 million) vs. the prior corresponding period. This increase reflects an increased investment in discovery activities, but also reflects the impact of the weaker Yen. JPY 414 million (US$2.8 million) has been included for R&D expenses relating to NPJ/NPK. G&A expenses totalled JPY 3,650 million (US$24.6 million), an increase of JPY 2,541 million (US$16.2 million) vs. the prior corresponding period. This increase was primarily due to incremental spend on personnel and professional fees to strengthen our organizational capabilities, as well as the cost of integrating our IT systems and unifying the Group under the Nxera Pharma brand. JPY 2,049 million (US$13.8 million) has been included for G&A expenses relating to the NPJ/NPK businesses, including an amortization charge on Idorsia related intangible assets. Operating loss totalled JPY 3,076 million (US$20.7 million) vs. an operating loss of JPY 1,964 million (US$14.8 million) in the prior corresponding period. This increase reflects the combined effect of all movements explained above. Loss before income tax totalled JPY 2,796 million (US$18.8 million) vs. a loss before income tax of JPY 1,863 million (US$14.1 million) in the prior corresponding period. This increase reflects the combined effect of all movements explained above. Net loss for the three-month period ended 31 March 2024 totalled JPY 3,281 million (US$22.1 million) vs. a net loss of JPY 1,402 million (US$10.6 million) in the prior corresponding period. This increase reflects the combined effect of all movements explained above. Core operating loss** totalled JPY 931 million (US$6.3 million) vs. a core operating loss of JPY 1,465 million (US$11.1 million) in the prior corresponding period. Cash and cash equivalents as at 31 March 2024 amounted to JPY 46,515 million (US$307.3 million) having decreased by JPY 2,550 million (US$40.6 million) from the beginning of the year. *Convenience conversion to US$ at the following rates: FY 2024: 1US$ =148.40 JPY; FY 2023: 1US$ =132.32 JPY; 31 Mar 2024: 1US$ = 151.35 JPY; 31 Dec 2023: 1US$ = 141.03 JPY ** Core operating profit / loss is an alternative performance measure which adjusts for material non-cash costs and one-off costs in order to provide insights into the recurring cash generation capability of the core business. –END– About Nxera Pharma Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery “NxWave™” platform to provide a sustainable source of best- or first-in-class candidates. Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor Relations Kentaro Tahara, VP Investor Relations and Corporate Strategy Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures Maya Bennison, Communications Manager +81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life MEDiSTRAVA Consulting (for International Media) Mark Swallow, Frazer Hall, Erica Hollingsworth +44 (0)203 928 6900 | Nxera@medistrava.com Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Attachment FY24Q1 E_Tanshin_Final_0509

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023. The full report can be found by clicking here. Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional. This progress is enabling the Group to accelerate its development in 2024 as an integrated, technology powered, commercial-stage biopharmaceutical company focused on cutting-edge science and delivering life-changing medicines for patients in Japan and globally. “We continue to accelerate business integration following the acquisition of Idorsia Pharmaceuticals Japan Ltd (“IPJ”) and Idorsia Pharmaceuticals Korea Co., Ltd (“IPK”), which has brought an exciting new dimension to our Group including the potential for many strategic development and commercial opportunities. We embark on this next phase of our journey as a well-financed organization and with a clear vision to create value for all our stakeholders and I want to thank all our employees for their efforts in making this a reality.” Operational Highlights for Q4 2023 Landmark investment of ~JPY8 billion (~USD54m) into Sosei Group from new OPF1 fund operated by JIC Venture Growth Investments Co., Ltd., an affiliate of Japan Investment Corporation – in conjunction with a share offering and convertible bond restructuring to finance the Group’s strategic growth initiatives; to extend the maturity pro its debt; and further strengthen its financial base. Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing. New Drug Application submitted in Japan for the approval of daridorexant, a novel dual orexin receptor antagonist, for the treatment of adult patients with insomnia – in relation to the submission, the Group received JPY 1.5 billion, which has been recognized as revenue in Q4 2023. Partner Neurocrine confirmed its plans to evaluate two new muscarinic agonist candidates in Phase 1 studies – both NBI-1117569 (a muscarinic M4-preferring agonist) and NBI-1117567 (a muscarinic M1-preferring agonist) are oral compounds that may have the potential to treat neurological and neuropsychiatric conditions. A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024. Partner Pfizer entered a new oral small molecule GLP-1 receptor agonist into a Phase 1 clinical trial targeting metabolic diseases – PF-06954522 was discovered by Pfizer scientists during a multi-target research collaboration in which Pfizer had access to Sosei Heptares’ StaR® technology. Discussions underway with GSK to regain full ownership of GSK43814061, a clinic-ready, first-in-class, oral GPR35 agonist targeting Inflammatory Bowel Diseases (“IBD”) – upon regaining ownership, the Group expects to proceed with a planned UK Phase 1 trial of GSK43814061 while determining the optimal strategy for the further clinical development and/or re-partnering of the program. US$3.75 million milestone payment received from partner Genentech – the discovery-based payment is related to progression of a potential first-in-class project targeting an undisclosed GPCR. Genentech will now be responsible for further development and commercialization of this potential new medicine. Strong progress in collaborations with leading technology companies Kallyope – identification, validation and nomination of a first GPCR target to enter a therapeutic discovery program for gastrointestinal diseases, Verily – launching a new discovery program based on the successful validation and nomination of a GPCR target for immune-mediated diseases with an initial indication focus of IBD, and PharmEnable Therapeutics – expansion of a collaboration to drive discovery of novel small molecule drug candidates against a second neurological disease target. Operational Highlights for Full Year 2023 Transformational acquisition of Idorsia’s pharmaceutical business in Japan and APAC – achieves key strategic milestone to become a fully integrated biopharmaceutical company: Adds complementary late-stage clinical development capability with profitable and fast-growing commercial operations in Japan. Brings highly experienced team, with proven clinical development and commercial launch track record. Lean, go-to-market commercial model, well positioned to scale rapidly to generate significant value from Japan and APAC geographic expansion. Includes Japan and APAC (ex-China) rights to two medicines with significant growth potential (PIVLAZ®) and daridorexant, as well as exclusive options and selected rights to up to seven other products from Idorsia’s clinical development pipeline. Purchase price of JPY65 billion is fully funded from existing cash (JPY25 billion) and new JPY40 billion long-term, low-rate corporate loan. First subject dosed with wholly owned HTL0048149 in Phase 1 trial – HTL’149 is a first-in-class GPR52 agonist designed by the Company as a once-daily oral treatment to address positive and negative symptoms and cognitive impairment in schizophrenia patients without the adverse effects typically associated with existing antipsychotic drugs. First patient dosed with cancer immunotherapy candidate HTL0039732in Phase 1/2a trial – HTL’732 is an orally available small molecule EP4 antagonist for advanced solid tumors being evaluated under an agreement with Cancer Research UK. Partner Neurocrine Biosciences initiated Phase 1 clinical study with NBI-1117570 – an investigational, oral, muscarinic M1/M4 selective dual agonist that may have the potential to treat neurological and neuropsychiatric conditions. Partner Tempero Bio received FDA clearance to advance clinical development of TMP-301 for alcohol and substance use disorders – TMP-301 (formerly HTL0014242) is a selective, orally available mGluR5 negative allosteric modulator (NAM) candidate discovered by Sosei Heptares and out-licensed to Tempero Bio. Sosei Group’s share listing elevated to the Tokyo Stock Exchange Prime Market – shortly after, Sosei Group shares were included in the Tokyo Stock Price Index (TOPIX). Changes to Board and Executive Management team – Ms. Eiko Tomita, a highly experienced pharmaceutical executive, was elected as an Independent External Director. Ms. Candelle Chong was promoted to Executive Vice President and Chief of Staff. Post-period Highlights Appointment of Chief Operating Officer – Mr. Toshihiro Maeda was appointed to this newly created role at Sosei Heptares to lead the post-acquisition integration of IPJ, and global technical operations, including manufacturing, supply chain and quality assurance, for the enlarged business in Japan and the Asia-Pacific region. Financial Highlights Revenue totalled JPY 12,766 million (US$90.8 million*), a decrease of JPY 2,803 million (US$27.7 million) vs. the prior corresponding period. The decrease is primarily due to the decrease in revenue related to upfront fees and milestone income due to signing no new partnership agreements and the occurrence of four milestone events in the current period vs. two upfront fee and five milestone events in the prior corresponding period, partially offset by the increase in pharmaceutical product sales due to the inclusion of IPJ in the scope of consolidation in July 2023, which resulted in the addition of PIVLAZ® sales. R&D expenses totalled JPY 10,075 million (US$71.7 million), an increase of JPY 2,621 million (US$14.9 million) vs. the prior corresponding period. This increase reflects an increased investment in discovery activities, but also reflects the impact of the weaker Yen. JPY 881 million (US$6.3 million) has been included for R&D expenses relating to IPJ and IPK. G&A expenses totalled JPY 9,965 million (US$70.9 million), an increase of JPY 5,588 million (US$37.6 million) vs. the prior corresponding period. This increase is primarily due to the inclusion of non-recurring M&A related costs. JPY 3,755 million (US$26.7 million) has been included for G&A expenses relating to IPJ/IPK. Operating loss totalled JPY 9,526 million (US$67.8 million) vs. an operating profit of JPY 3,436 million (US$26.2 million) in the prior corresponding period. This increase reflects the combined effect of all the movements explained above. Loss before income tax totalled JPY 10,680 million (US$76.0 million) vs. a profit before income tax of JPY 1,078 million (US$8.2 million) in the prior corresponding period. This increase reflects the combined effect of all the movements explained above. Net loss for the year ended 31 December 2023 totalled JPY 7,193 million (US$51.2 million) vs. a net profit of JPY 382 million (US$2.9 million) in the prior corresponding period. This increase reflects the combined effect of all the movements explained above. Core operating loss** totalled JPY 3,076 million (US$21.9 million) vs. a core operating profit of JPY 5,856 million (US$44.6 million) in the prior corresponding period. Cash and cash equivalents as at 31 December 2023 amounted to JPY 49,065 million (US$347.9 million) having decreased by JPY 17,492 million (US$159.1 million) from the beginning of the year. This decrease was primarily due to the transaction with Idorsia. *Convenience conversion to US$ at the following rates: FY 2023: 1US$ =140.53 JPY; FY 2022: 1US$ =131.30 JPY; 31 Dec 2023: 1US$ = 141.03 JPY; 31 Dec 2022: 1US$ = 131.27 JPY **Core operating profit / loss is an alternative performance measure which adjusts for material non-cash costs and one-off costs in order to provide insights into the recurring cash generation capability of the core business. -ENDS- About Sosei Heptares Sosei Heptares is a fully integrated biopharmaceutical company focused on bringing life-changing medicines based on world-class science to patients globally. Our vision is to become one of Japan’s global biopharmaceutical champions. Our global business combines our world-leading GPCR-targeted StaR® technology, structure-based drug design and early development capabilities in the UK with a highly experienced clinical development capability and a commercial operation in Japan. We are leveraging these capabilities to generate and advance a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases. We intend to develop these opportunities for patients in Japan and globally both internally and through our partnerships with global biopharmaceutical companies and emerging technology companies. Sosei Heptares operates from key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea). “Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies. For more information, please visit LinkedIn: @soseiheptaresco | X: @soseiheptaresco | YouTube: @soseiheptaresco Enquiries: Sosei Heptares – Media and Investor Relations Kentaro Tahara, VP Investor Relations and Corporate Strategy Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures Maya Bennison, Communications Manager +81 (0)3 5210 3399 | +44 (0)1223 949390 | IR@SoseiHeptares.com MEDiSTRAVA Consulting (for International Media) Mark Swallow, Frazer Hall, Erica Hollingsworth +44 (0)203 928 6900 | SoseiHeptares@medistrava.com Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Sosei Group Corporation’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Attachment FY23YE_Tanshin_ Sosei Heptares